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CASE REPORT
Atypical hemolytic uremic syndrome 
in first trimester pregnancy successfully treated 
with eculizumab
Gabriela Andries1, Michael Karass1* , Srikanth Yandrapalli1, Katherine Linder1, Delong Liu2, John Nelson2, 
Rahul Pawar3 and Savneek Chugh3
Abstract 
Background:  Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic 
microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome 
is caused mostly by dysregulation of alternative complement pathway secondary to genetic mutations. Most of the 
cases reported have been in the post-partum period. We report a rare case of a patient who presents with thrombotic 
microangiopathy in the first trimester of her eleventh pregnancy and was successfully treated with eculizumab.
Case presentation: A 30-year-old woman presented at 10 weeks of gestation with hypertension, hemolytic anemia, 
thrombocytopenia, and acute kidney injury, consistent with thrombotic microangiopathy. She was managed initially 
with daily plasmapheresis. However, her kidney function did not recover, requiring hemodialysis. ADAMTS13 activity 
was later found to be within normal limit, hence diagnosis of atypical hemolytic uremic syndrome was strongly con-
sidered at that time and she was immediately treated with anti-C5 humanized monoclonal antibody (eculizumab). 
The patient responded well (resolution of thrombotic microangiopathy and recovery of renal function) to eculizumab, 
with continued remission after discharge and successfully delivered a healthy baby at term without any peripartum 
complications.
Conclusion: Early recognition of atypical hemolytic uremic syndrome is often difficult as several other conditions 
also manifest as thrombotic microangiopathy during pregnancy, causing delay in initiating appropriate treatment. 
Our case suggests that treatment of atypical hemolytic uremic syndrome in early trimester of pregnancy with eculi-
zumab results in good outcome to mother and fetus.
Keywords: Thrombotic microangiopathy (TMA), Atypical hemolytic uremic syndrome (aHUS), Eculizumab, 
Pregnancy, First trimester
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Background
Thrombotic microangiopathy (TMA) is a group of dis-
orders with a common pathological pattern of injury 
characterized by fibrin and/or platelet thrombi in the 
microvasculature causing consumptive thrombocytope-
nia, hemolytic anemia and end organ damage. Diseases 
causing primary TMA are divided into two broad cat-
egories: thrombotic thrombocytopenic purpura (TTP) 
and hemolytic uremic syndrome (HUS). In TTP, sys-
temic clumping of platelets is caused by unusually large 
multimers of von Willebrand factor as a consequence of 
deficient ADAMTS13 activity (a von Willebrand factor-
cleaving metalloprotease). Hemolytic uremic syndrome 
(HUS), on the other hand, is not associated with the 
absence or severe reduction of ADAMTS13 activity and 
has predominant renal involvement.
HUS is divided into typical (shiga-toxin mediated 
or STEC) HUS and atypical HUS (aHUS) [1]. Atypi-
cal HUS occurs due to dysregulation of the alternative 
complement pathway, leading to complement-mediated 
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endothelial damage resulting in TMA and organ injuries. 
Pregnancy has been associated with a wide spectrum of 
TMA, ranging from HUS, TTP, and HELLP (hemolysis, 
elevated liver enzymes, and low platelet count). Distinc-
tion among these three syndromes is often difficult as 
they share similar clinical features. Establishing the right 
diagnosis is very crucial for implementing the optimal 
treatment strategies [2]. We present a very rare case of 
a young lady who presented during the first trimester 
of pregnancy with severe thrombocytopenia, hemolytic 
anemia, and acute kidney injury (AKI). She was initially 
suspected to have TTP, but later diagnosed with an unu-
sually early presentation of atypical HUS with dramatic 
clinical recovery and successful pregnancy outcome with 
the use of eculuzimab.
Case report
A 30-year-old woman, presented to the hospital at 
10  weeks of gestation, with nausea, vomiting, few epi-
sodes of watery non-bloody diarrhea, and dark colored 
urine for the past 5 days. She had multiple abortions in 
the past and was having her 11th pregnancy, all with the 
same partner. Her past medical history is significant for 
hereditary pancreatitis (R117 H gene mutation) requir-
ing multiple surgeries, five miscarriages (all in the first 
trimester), and self-resolving thrombocytopenia during 
the last trimester of her previous viable pregnancies. She 
tested negative for antiphospholipid syndrome (negative 
anticardiolipin antibodies, anti-beta2-glycoprotein I anti-
bodies, and lupus anticoagulant). She denied any bleed-
ing or bruising symptoms including hematuria, epistaxis, 
or vaginal bleeding.
She presented with a blood pressure of 156/99 mmHg, 
heart rate of 80 beats/min, respiratory rate of 16 breaths/
min, oral temperature of 98.4°F, and peripheral oxygen 
saturation of 97% on ambient air. Physical examination 
was unremarkable, except for petechiae on the lower 
and upper extremities. Initial laboratory investigations 
revealed a hemoglobin level of 7.8 mg/dL, platelet count 
of 15,000/mm3, presence of schistocytes on peripheral 
smear, serum creatinine of 2.44  mg/dL, elevated lac-
tate dehydrogenase (LDH) at 1847  U/L, aspartate ami-
notransferase (AST) 58  U/L, alanine aminotransferase 
(ALT) 17  U/L, alkaline phosphatase 45  U/L, total bili-
rubin 1.7 mg/dL, direct bilirubin of 0.4 mg/dL, albumin 
3.2 mg/dL, and haptoglobin <8 mg/dL.
Urinalysis showed 3+ proteinuria and 3+ blood with 
spot urine protein-to-creatinine ratio of 5600  mg/g. 
Her coagulation studies were normal with INR 0.95, PT 
10.4  s, PTT 25.5  s and fibrinogen level of 311  mg/dL 
(Table 1).
All viral serologies for hepatitis B and C, HIV and Par-
vovirus B-19 were all negative. With that presentation a 
diagnosis of thrombotic microangiopathy (TMA) was 
made. ADAMTS-13 activity and inhibitor assay was 
sent to the Blood Center of Wisconsin to rule out TTP 
and daily plasmapheresis was started since day 1 of her 
hospitalization along with oral prednisone at 1  mg/kg/
day. No STEC testing was performed as the patient had 
normal bowel movements. Despite daily plasmapher-
esis, the patient required multiple transfusions to main-
tain her hemoglobin levels above 8 (Fig. 1) and remained 
hypertensive requiring 2 antihypertensive medications. 
Her renal function continued to worsen (Fig.  2) requir-
ing hemodialysis on the 4th day of initiating daily plas-
mapheresis. On hospitalization day-4, ADAMTS13 
activity was reported to be normal at 129%. Diagnosis 
of aHUS was strongly considered at that time and the 
decision was made to discontinue plasmapheresis and 
to start the patient on eculizumab at a dose of 900  mg 
intravenously weekly. Complement gene mutation tests 
were ordered as part of aHUS work-up (which was sent 
to Genomic and Pathology Services of Washington Uni-
versity Medical School in St. Louis). Due to the patient’s 
clinical instability, rifampin was initiated prophylactically 
with meningococcal vaccination given after initiating 
treatment with eculizumab. On Day-15 of hospitaliza-
tion (after two doses of weekly eculizumab) laboratory 
values started to improve. Her platelet count increased to 
124,000/mm3 (Fig. 3), hemoglobin levels remained above 
8.5  mg/dL without any transfusion (Fig.  1), and LDH 
trended down to 520 U/L (Fig. 4). Her AKI was resolving 
Table 1 Patient’s laboratory result at initial presentation
Test Patient’s result Normal reference value
Hemoglobin (g/dL) 7.8 11.6–15
Hematocrit (%) 22.1 36–45
WBC (K/CU MM) 7.9 4.5–10.8
Platelet count (K/U MM) 15 160–410
BUN (mg/dL) 65 6–22
Creatinine (mg/dL) 2.44 0.57–1.11
LDH (U/L) 1847 125–220
AST (U/L) 58 4–35
ALT (U/L) 17 6–55
Total bilirubin (mg/dL) 1.7 0.2–1.3
Direct bilirubin (mg/dL) 0.4 0.1–0.6
Haptoglobin (mg/dL) <8 13–281
Amylase level (U/L) 30 22–100
Lipase level (U/L) 8 8–78





Fibrinogen level (mg/dL) 432 180–400
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with good urine output (BUN of 18 mg/dL and creatinine 
2.44  mg/dL). Hemodialysis was then stopped and the 
dialysis catheter was removed. She clinically improved 
and remained hemodynamically stable. Patient was dis-
charged home 18 days after admission.
Genetic analysis result came back few weeks after 
her discharge, revealing that she had no pathogenic 
sequence variants identified. Genes sequenced were C3, 
CD46, CFB, CFH, CFI, DGKE, and THBD. Patient was 
given induction dose of 900  mg intravenous (IV) eculi-
zumab every week for 4 doses, followed by 1200 mg IV 
biweekly for the rest of her pregnancy as an outpatient. 
No maternal or fetal complications were reported during 
the entire pregnancy and on the 36th gestational week, 
she delivered a healthy baby through cesarean section 
with no peri-operative complications. Around the time 
of her delivery, her Hb was 10.9 mg/dL, BUN was 9 mg/
dL, creatinine of 0.52 mg/dL, and LDH of 163 U/L. She 
Fig. 1 Patient’s hemoglobin trend during hospitalization and peripartum period. Patient’s hemoglobin trend during hospitalization and peripartum 
period shows a mild increase in hemoglobin after starting eculizumab
Fig. 2 Patient’s creatinine trend during hospitalization and peripartum period. Patient’s creatinine trended down during hospitalization after start-
ing eculizumab with a return of creatinine back to baseline in the peripartum period
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was discharged home 3  days postpartum. She contin-
ues to receive two weekly eculizumab infusions after 
her delivery, has had no TMA recurrence for more than 
20 months on eculizumab therapy and with healthy baby.
Discussion
Dysregulation of the alternative complement pathway 
is recognized in 60% of aHUS cases [3, 4]. Uncontrolled 
activation of the terminal complement leads to the for-
mation of C5b-9 complex (Membrane Attack Complex 
or MAC), causing endothelial cell damage and leading to 
the development of pro-coagulant and pro-inflammatory 
states, which manifest as TMA [2]. Over 100 complement 
gene mutations predisposing to aHUS have been identi-
fied. These include mutations in C3, CD46 (MCP), CFB, 
CFH, CFI, CFHR1, CFHR3, CFHR4, DGKE, and THBD 
leading to uncontrolled activation of alternative of com-
plement pathway [4]. Mutations include loss-of-function 
of complement regulatory proteins, polymorphisms, 
hybrid gene encoding for a CHFR1/CFH fusion protein, 
Fig. 3 Patient’s platelet count trend during hospitalization and peripartum period: Patient’s platelets showed a steady increase after the patient was 
started on eculizumab
Fig. 4 Patient’s LDH trend during hospitalization and peripartum period: The LDH initially increased after the first dose of eculizumab, then steadily 
decreased, with persistent low level in the peripartum period
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and from gain-of-function mutations of C3 and CFB. 
Penetrance of these mutations is estimated at 40–60% 
penetrance with additional complement amplifying con-
ditions needed for disease manifestation in predisposed 
individuals [2, 3]. These include infection, certain drugs 
(chemotherapeutic agents, immunotherapeutic agents, 
antiplatelet agents, oral contraceptives, anti-inflamma-
tory agents), malignancy, post-transplantation, and preg-
nancy [4].
Although aHUS is a complement mediated disease pro-
cess, low levels of serum C3 are not specific for aHUS and 
hence their testing is not of diagnostic value in this set-
ting [5]. Normal C3 values do not exclude mutations or 
antibodies against the complement system [6]. Recently, 
Gavriilaki et al. [7] developed an interesting modification 
of the Ham test (which is used for diagnosis of paroxys-
mal nocturnal hemoglobinuria (PNH)) to rapidly diag-
nose aHUS and to differentiate it from other causes of 
TMA. This test is based on complement-mediated apop-
tosis and death in glycosylphosphatidylinositol-anchored 
complement regulatory proteins deficient cells. This will 
have important clinical implications and also might help 
in identifying patients at higher risk of developing aHUS 
[6].
Genetic testing for mutations of the alternative com-
plement pathway are very expensive, take several weeks, 
and is informative in only 50–60% of the cases [7]. One 
review article proposed that diagnosing aHUS in a 
patient with TMA would require demonstration of AP 
dysregulation biomarkers (for example, by elevation of 
plasma Ba levels, C4d, and terminal complement acti-
vation UC5a/Cr, Uc5b-9/Cr), followed by reassessment 
of proximal complement activation after specific treat-
ment which targets terminal complement activation (e.g. 
eculizumab). In patients with aHUS, persistent activa-
tion of proximal pathway should still occur despite the 
treatment, and this can be demonstrated with an indi-
rect Ham test. However, validation of this test in larger 
cohorts will help in diagnosing aHUS early in the course 
of the disease instead of waiting to rule out other causes 
[8].
Our patient had laboratory evidence of TMA with ane-
mia, thrombocytopenia, schistocytes, high LDH, and a 
reduced haptoglobin level, correlating with the develop-
ment of AKI. Testing for ADAMTS13 was negative and 
liver enzyme tests were normal, thus ruling out TTP and 
HELLP. This initial step is very important because the 
management varies among different causes of TMA and 
early initiation of appropriate treatment can have signifi-
cant effect on morbidity and mortality. The presence of 
worsening AKI pointed towards aHUS rather than TTP. 
Typical HUS as alternative diagnosis was considered, 
but she presented with no gastrointestinal symptoms to 
our hospital, rendered us questioning the value of Shiga 
toxin-producing Escherichia coli (STEC) screening test 
at that time. The fact that the patient’s condition contin-
ued to deteriorate after supportive treatment and plasma 
exchange, makes typical or STEC-HUS unlikely to be the 
diagnosis.
In a case series published by Fakhouri et  al. [9] 21% 
of aHUS cases were during pregnancy, with the highest 
reported cases during the second pregnancy and about 
80% of the presentations were at the time of delivery or 
immediately post-partum. Complement activating con-
ditions, such as pregnancy complications (preeclampsia 
and HELLP), renal transplantation, autoimmune disease, 
and certain medications have been illustrated as condi-
tions that tend to unmask and precede onset of aHUS in 
predisposed individuals [10]. Our patient presented with 
aHUS in the first trimester, a very rare occurrence. This 
is postulated to be related to the number of pregnancies 
she had, with each pregnancy causing more robust com-
plement activation secondary to induction of anti-HLA 
antibodies when fetal cells transverse to the maternal 
circulation.
It is also worth noting that our patient has a significant 
medical history of hereditary pancreatitis, which could 
potentially play a role in subclinical complement acti-
vation by a chronic inflammatory process. Hereditary 
pancreatitis due to R 117 H mutation is a rare genetic 
disorder, in which Arg-His substitution at residue 117 
of trypsinogen gene causes failure to inactivate trypsin, 
which in turns, results in autodigestion of the pancreas 
[11].
The high morbidity and mortality of aHUS indicates 
a severe and unmet medical need. Traditionally, aHUS 
has been managed by various modalities including anti-
coagulants, immunosuppressive therapies, and plasma 
exchange and/or plasma infusion; with a poor progno-
sis [12]. Plasma exchange or plasma infusion is gener-
ally poorly tolerated and has inconsistent results. In 
patients with a CFH mutation, who developed a TMA, 
22% of patients and 30% of patients, treated with plasma 
exchange progressed to ESRD or death, respectively [12, 
13]. The poor outcome on plasma exchange therapy is 
attributed to directly activated platelets with complement 
fragments deposited on platelet cell surfaces. Normaliza-
tion of platelet count and LDH induced by plasma-based 
therapy had no effect on elevated level of proximal and 
terminal complement pathway activation, endothelial cell 
activation, endothelial cell injury, ongoing coagulation 
pathway activation, systemic inflammation, and ongoing 
deterioration in renal function [8].
For patients who develop ESRD, kidney transplant is 
pursued; however, transplant failure occurs in 67–81% 
of patients with plasma infusion non-MCP mutation 
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aHUS [13]. On the other hand, combined liver–kid-
ney transplantation has been more successful than kid-
ney transplantation alone, possibly curing aHUS [12, 
13]. Unfortunately, due to the limited number of organs 
available and the high risk of the procedure, it is less fre-
quently attempted [13, 14]. Eculizumab is the first treat-
ment to offer a highly specific complement-targeted 
therapeutic option for patients with TMA.
Eculizumab is a high-affinity humanized monoclo-
nal antibody that binds to and blocks the cleavage of 
C5 into the inflammatory, prothrombotic, and lytic C5a 
and C5b-9 terminal complement components, leaving 
the upstream components, most notably C3a intact. By 
blocking complement hyper activation and dysregula-
tion, it reduces hemolysis, prothombotic activity, and 
inflammation associated with aHUS including ESRD and 
death. It is a pregnancy category C drug, safely used in 
pregnant women. Limited study by Hallstensen et al. [15] 
found that very low level eculizumab and eculizumab-
C5 complex were detected in the serum of newborns of 
pregnant women treated with eculizumab, however the 
newborns still have a fully functional complement activ-
ity. Few case reports and series have also demonstrated 
long-term efficacy and safety of Eculizumab as first line 
treatment in neonates and infants who suffered from 
aHUS. Similar to our patient, neonates and infants in the 
studies also showed complete recovery of the renal func-
tion after initiation of Ezulizumab [16, 17].
By inhibiting the late elements of the complement cas-
cade system, patients are predisposed to infection by 
encapsulated bacteria, including Neisseria meningitidis 
[18–21]. Therefore, patients who have not been vacci-
nated against N. meningitidis should receive a quadriva-
lent meningococcal vaccine at least 2 weeks prior to the 
first dose of eculizumab [22, 23]. In patients like ours 
where we need to give the therapy immediately, prophy-
lactic antibiotics can be administered till then. One retro-
spective study during STEC-mediated HUS outbreak in 
Germany also reported simultaneous treatment with anti-
biotic for meningococcal prophylaxis in 98% of patients 
treated with eculizumab [24, 25]. Rifampin, as one of the 
antibiotic options, was proven effective at eradicating N. 
meningitidis up to four weeks after treatment when com-
pared with placebo [26, 27]. This case and the discussion 
highlight the use of the monoclonal antibody, eculizumab, 
as a viable option in the treatment of aHUS in pregnant 
women. It also describes the pathophysiology of aHUS as 
it relates to the complement pathway.
Conclusion
Pregnancy-associated atypical hemolytic syndrome is 
a rare disorder, caused by dysregulation in complement 
activation, and associated with very high morbidity and 
mortality. As several other conditions can also cause 
TMA in pregnancy, physicians often face difficulty in 
diagnosing aHUS. This is very important, as early rec-
ognition and initiation of treatment with eculizumab, an 
anti-C5 therapy, has been proven to be highly effective. 
Our case suggests that early treatment with eculizumab 
in first trimester until the end of pregnancy was safely 
tolerated by both mother and fetus, resulted in remission 
and recovery of kidney function.
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